EXTH-52. EGFRvIII: A NEW PREDICTIVE BIOMARKER FOR TEMOZOLOMIDE RESPONSE IN MGMT PROMOTOR METHYLATED GLIOBLASTOMA PATIENTS

Despite many clinical efforts, the prognosis of GBM patients has not improved in the last 10 years. Epigenetic silencing of the O6-methylguanine-DNA-methyltransferase (MGMT) gene is the only predictive biomarker that is associated with temozolomide (TMZ) response. The establishment of new biomarkers...

Full description

Saved in:
Bibliographic Details
Published in:Neuro Oncol
Main Authors: Struve, Nina, Brend, Tim, Stead, Lucy, Binder, Zev A, Ott, Leonie, Muller-Goebel, Justus, Hoffer, Konstatin, Morrissette, Jennifer J D, Petersen, Cordula, Rothkamm, Kai, O’Rourke, Donald, Short, Susan C, Kriegs, Malte
Format: Artigo
Language:Inglês
Published: Oxford University Press 2017
Subjects:
Abstracts
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692225/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.344
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items